Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1132403

	registered interest
	date	17/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Lumacaftor/ivacaftor
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what contingency plans his Department has put in place in the event that Vertex declines NHS England’s latest offer for the supply of Orkambi.
	tabling member constituency	Birmingham, Selly Oak
	tabling member printed	Steve McCabe
	uin	265417
	answer	answer is ministerial correction date of answer 20/06/2019 answer text <p>NHS England is leading the negotiations with Vertex and has made a revised and improved offer to Vertex that would provide immediate funding for Orkambi, and Symkevi in advance of assessment by the National Institute for Health and Care Excellence (NICE), and expanded access to Kalydeco which is already funded on the National Health Service for certain patients.</p><p>The Government fully supports NICE and NHS England in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department’s approach remains to urge Vertex to accept NHS England’s generous offer, but we will explore other options to ensure patients can access treatments as soon as possible.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 265418 question first answered 20/06/2019 09:33:36 answering member 4455 label Biography information for Seema Kennedy
	tabling member	298 label Biography information for Steve McCabe

1122669

	registered interest
	date	24/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Lumacaftor/ivacaftor
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what estimate his Department has made of the value of packs of Orkambi that have been disposed of while negotiations between NHS England and Vertex Pharmaceuticals are ongoing.
	tabling member constituency	North East Hampshire
	tabling member printed	Mr Ranil Jayawardena
	uin	247136
	answer	answer is ministerial correction date of answer 03/05/2019 answer text <p>The Department has made no such estimate.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 03/05/2019 13:18:10 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4498 label Biography information for Mr Ranil Jayawardena

1104818

	registered interest
	date	25/03/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Lumacaftor/ivacaftor
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to secure a deal with Vertex on access for patients to the drug Orkambi on the NHS.
	tabling member constituency	Leeds North West
	tabling member printed	Alex Sobel
	uin	236525
	answer	answer is ministerial correction date of answer 01/04/2019 answer text <p>The National Institute for Health and Care Excellence (NICE) and NHS England are leading the dialogue with Vertex Pharmaceuticals on access to their portfolio of cystic fibrosis medicines, including Orkambi.</p><p> </p><p>The Government fully supports the approach that NICE and NHS England are adopting. It is crucial that patients have access to the most effective and innovative medicines at a price that represents value to the NHS.</p><p> </p><p>My Rt. hon. Friend the Secretary of State for Health and Social Care held a meeting on 11 March with all the parties to discuss how best to reach a deal so that people with cystic fibrosis and their families can benefit as soon as possible. Vertex, NICE and NHS England subsequently met on Thursday 21 March and have agreed to continue discussions.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 01/04/2019 11:40:40 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	4658 label Biography information for Alex Sobel

1088522

	registered interest
	date	13/03/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Lumacaftor/ivacaftor
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 19 January 2018 to Question 122336 on Orkambi, whether he has made an estimate of the potential savings accruing to the public purse from reduced hospital admissions in the event that Orkambi is made available on the NHS.
	tabling member constituency	Glasgow East
	tabling member printed	David Linden
	uin	232091
	answer	answer is ministerial correction date of answer 21/03/2019 answer text <p>As stated in my answer on 19 January 2018, the Department has made no estimate.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 21/03/2019 16:17:12 answering member 4067 label Biography information for Steve Brine
	tabling member	4640 label Biography information for David Linden

1059846

	registered interest
	date	12/02/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Lumacaftor/ivacaftor
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will place in the Library a copy of his response to the technical submission, contained in the letter to him dated 31 January 2019 from patients and campaigners on issuing a Crown Use License to make Orkambi available to all eligible patients in England; and if he will make a statement.
	tabling member constituency	Brighton, Pavilion
	tabling member printed	Caroline Lucas
	uin	220176
	answer	answer is ministerial correction date of answer 20/02/2019 answer text <p>We have received the letter dated 31 January and we will respond in due course.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 20/02/2019 17:42:05 answering member 4067 label Biography information for Steve Brine
	tabling member	3930 label Biography information for Caroline Lucas

1060036

	registered interest
	date	12/02/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Lumacaftor/ivacaftor
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the potential merits of using a Crown licence obtain the drug Orkambi at an affordable price.
	tabling member constituency	East Antrim
	tabling member printed	Sammy Wilson
	uin	220162
	answer	answer is ministerial correction date of answer 20/02/2019 answer text <p>It is right that patients should have access to cost-effective, innovative medicines at a price that is affordable to the National Health Service. As explained in the adjournment debate on 4 February, the Government is clear Crown Use is not a quick or easy solution but it is important we consider all options.</p><p> </p><p>The manufacturer, Vertex, needs to agree the very generous offer that has been made so that patients who need Orkambi are able to access it on the NHS. This is in the best interests of patients.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 20/02/2019 17:27:59 answering member 4067 label Biography information for Steve Brine
	tabling member	1593 label Biography information for Sammy Wilson

1056732

	registered interest
	date	07/02/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Lumacaftor/ivacaftor
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what progress his Department has made on securing the availability of Orkambi on the NHS for patients with cystic fibrosis.
	tabling member constituency	Sheffield, Brightside and Hillsborough
	tabling member printed	Gill Furniss
	uin	218344
	answer	answer is ministerial correction date of answer 12/02/2019 answer text <p>The National Institute for Health and Care Excellence (NICE) and NHS England are leading the dialogue with Vertex Pharmaceuticals around access to their portfolio of cystic fibrosis medicines. It is critical that Vertex now re-engages fully with the NICE appraisal process and gives serious consideration to the portfolio deal offer that NHS England made at the end of July. This deal would provide immediate access for patients to all Vertex licensed medicines and future pipeline products once licensed and in advance of the individual NICE appraisals concluding.</p><p> </p><p>The Government fully supports the approach that NICE and NHS England are adopting. It is crucial that patients have access to the most effective and innovative medicines at a price that represents value to the National Health Service.</p><p> </p><p>NHS England has proposed its best offer ever for a drug. This offer, in the region of £500 million over five years, is the largest ever commitment of its kind in the 70-year history of the NHS and would guarantee immediate and expanded access to both Orkambi and the drug Kalydeco for patients who need it. Whilst it is disappointing that Vertex has not taken up NHS England’s offer, we are encouraged that there is continued dialogue between all parties.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 12/02/2019 15:33:24 answering member 4067 label Biography information for Steve Brine
	tabling member	4571 label Biography information for Gill Furniss

1037028

	registered interest
	date	07/01/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Lumacaftor/ivacaftor
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent discussions he has had with (a) NHS England (b) NICE and (c) Vertex on access to Orkambi for cystic fibrosis sufferers; and if he will make a statement.
	tabling member constituency	Oxford West and Abingdon
	tabling member printed	Layla Moran
	uin	206035
	answer	answer is ministerial correction date of answer 15/01/2019 answer text <p>Officials in the Department have had a number of discussions with the National Institute for Health and Care Excellence (NICE) and NHS England on the availability of Orkambi. NICE and NHS England are leading the dialogue with Vertex Pharmaceuticals around access to its portfolio of cystic fibrosis medicines. It is critical that Vertex now re-engages fully with the NICE appraisal process and gives serious consideration to the portfolio deal offer that NHS England made at the end of July. This deal would provide immediate access for patients to all Vertex licensed medicines and future pipeline products once licensed and in advance of the individual NICE appraisals concluding. The Government fully supports the approach that NICE and NHS England are adopting.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 15/01/2019 16:12:27 answering member 4067 label Biography information for Steve Brine
	tabling member	4656 label Biography information for Layla Moran

1037196

	registered interest
	date	07/01/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Lumacaftor/ivacaftor
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what progress has been made in negotiations between NHS England and Vertex on the supply of Orkambi to treat people with cystic fibrosis.
	tabling member constituency	Wigan
	tabling member printed	Lisa Nandy
	uin	205913
	answer	answer is ministerial correction date of answer 10/01/2019 answer text <p>The National Institute for Health and Care Excellence (NICE) and NHS England are leading the dialogue with Vertex Pharmaceuticals around access to their portfolio of cystic fibrosis medicines. It is critical that Vertex now re-engages fully with the NICE appraisal process and gives serious consideration to the portfolio deal offer that NHS England made at the end of July. This deal would provide immediate access for patients to all Vertex licensed medicines and future pipeline products once licensed and in advance of the individual NICE appraisals concluding. The Government fully supports the approach that NICE and NHS England are adopting. It is crucial that patients have access to the most effective and innovative medicines at a price that represents value to the National Health Service.</p><p> </p><p>NHS England has proposed its best offer ever for a drug. This offer, in the region of £500 million over five years, is the largest ever commitment of its kind in the 70-year history of the NHS and would guarantee immediate and expanded access to both Orkambi and the drug Kalydeco for patients who need it. Whilst it is disappointing that Vertex has not taken up NHS England’s offer, we are encouraged that there is continued dialogue between all parties.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 10/01/2019 17:10:14 answering member 4067 label Biography information for Steve Brine
	tabling member	4082 label Biography information for Lisa Nandy

1012495

	registered interest
	date	22/11/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Lumacaftor/ivacaftor
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what progress he has made on the acquisition of Orkambi for the NHS.
	tabling member constituency	North East Hampshire
	tabling member printed	Mr Ranil Jayawardena
	uin	194795
	answer	answer is ministerial correction date of answer 27/11/2018 answer text <p>The National Institute for Health and Care Excellence (NICE) and NHS England are in dialogue with Vertex Pharmaceuticals around access to their portfolio of cystic fibrosis medicines. It is critical that Vertex now re-engages fully with the NICE appraisal process and gives serious consideration to the portfolio deal offer that NHS England made at the end of July. This deal would provide immediate access for patients to all Vertex licensed medicines and future pipeline products once licensed and in advance of the individual NICE appraisals concluding.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 27/11/2018 17:11:41 answering member 4067 label Biography information for Steve Brine
	tabling member	4498 label Biography information for Mr Ranil Jayawardena